Market Overview

Jim Cramer Advises His Viewers On BlackRock, Target And More

Related BIIB
The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut
The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent
Gritstone Oncology Prepares Final Terms For IPO (Seeking Alpha)
Related RF
Earnings Scheduled For July 20, 2018
Benzinga's Top Upgrades, Downgrades For June 18, 2018
These 5 Bank Stocks Are Near Buy Points: Investing Action Plan (Investor's Business Daily)

On CNBC's "Mad Money Lightning Round", Jim Cramer said Biogen Inc (NASDAQ: BIIB) could double if it meets its endpoints and it could lose 40 percent if it doesn't meet them. The company failed to meet the endpoints earlier, but now it claims that it has made them. Cramer added this stock in't for him, but he suggested viewers should make their own decision based on the risk-reward.

Cramer likes Regions Financial Corp (NYSE: RF) and other medium size banks.

Lockheed Martin Corporation (NYSE: LMT) is very good and it could recover, said Cramer. He prefers Raytheon Company (NYSE: RTN).

U.S. Bancorp (NYSE: USB) is one of Cramer's favorite banks. He thinks it could do quite well, but not instantly.

Cramer is a buyer of Target Corporation (NYSE: TGT). He thinks the stock is a winner.

This is a rare opportunity to buy BlackRock, Inc. (NYSE: BLK) when it's down, said Cramer. He would take advantage of it.

Posted-In: Jim Cramer mad money Lightning RoundMedia


Related Articles (BIIB + BLK)

View Comments and Join the Discussion!

A Peek Into The Markets: Dow Futures Fall Ahead Of Earnings

50 Biggest Movers From Yesterday